2002
DOI: 10.1128/iai.70.10.5790-5799.2002
|View full text |Cite
|
Sign up to set email alerts
|

Candida-Specific Antibodies during Experimental Vaginal Candidiasis in Mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
23
0

Year Published

2003
2003
2024
2024

Publication Types

Select...
7
2
1

Relationship

2
8

Authors

Journals

citations
Cited by 48 publications
(25 citation statements)
references
References 50 publications
2
23
0
Order By: Relevance
“…Animals were divided into 3 major groups per models. In vaginal infection model, 50 µl subcutaneous estradiol-valerate (10 mg/ml) was given to all mice three days prior to infection [11][12][13].…”
Section: Methodsmentioning
confidence: 99%
“…Animals were divided into 3 major groups per models. In vaginal infection model, 50 µl subcutaneous estradiol-valerate (10 mg/ml) was given to all mice three days prior to infection [11][12][13].…”
Section: Methodsmentioning
confidence: 99%
“…[77][78][79] More recently a comprehensive evaluation of Candida-specific IgG and IgA including subclasses (IgG1-4, IgA1-2) and secretory IgA (sIgA) in saliva showed no differences between HIV-negative and HIV-positive persons with or without OPC. 80 Therefore there appears little evidence for any deficiency or over expression of Candida-specific antibodies that could account for susceptibility to OPC.…”
Section: Local Immunitymentioning
confidence: 99%
“…For the model of VVC, female CBA/J (H-2 k ) mice in pseudoestrus were intravaginally inoculated with 5 ϫ 10 4 CFU of the C. albicans strains (26). We detected no differences in morphology or tissue burdens between CAI-12 and the null mutant in vaginal lavages recovered on days 4 and 7 postinfection (log CFU/ml for CAI-12, 3.34 Ϯ 0.35 at day 4 and 3.13 Ϯ 0.34 at day 7; log CFU/ml for the null mutant, 3.96 Ϯ 0.53 at day 4 and 2.54 Ϯ 0.89 at day 7) (P ϭ NS for both days).…”
Section: Vol 73 2005mentioning
confidence: 99%